Healthcare Stocks Sliding Near Close; Cyclacel Pharma Spikes After Anti-Tumor Drug Shows Added Promise

By Staff,

Shutterstock photo

Top Healthcare Stocks

JNJ -0.03%

PFE +0.54%

ABT -0.02%

MRK -0.60%

AMGN -0.15%

Healthcare stocks are mixed in late afternoon trade with the NYSE Healthcare Sector Index rising less than 0.1% while shares of healthcare companies in the S&P 500 are down about 0.1% as a group.

In company news, Cyclacel Pharmaceuticals Inc. ( CYCC ) is up nearly 30% at $4.93 a share after the drug-maker released updated data indicating its sapacitabine drug candidate has shown anti-tumor activity against a majority of ovarian cancer samples taken from patients, including resistant tumors.

"This observation may be directly related to the drug's mechanism which is enhanced in cancer cells with reduced capacity for DNA repair through the homologous recombination repair or HR pathway," said Dr. Judy Chiao, head of clinical development and regulatory affairs at CYCC.

The data were presented this week during the American Association of Cancer Research annual conference in Miami.

In other sector news,

(+) TECH, RW Baird upgrade to Outperform from Neutral with $90.00 price target.

(-) RNA, Said its prospective treatment for Duchenne muscular dystrophy did not meet its primary endpoint during Phase III testing of improving muscle function in boys and young men with the genetic mutation.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: CYCC

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by